

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 02,090-B)

In re Application of:

Bakthavatchalam et al.

Serial No. 09/910,442

Filed: July 20, 2001

For: Capsaicin Receptor Ligands

Before Examiner:

Not yet assigned

Art Unit: 1614

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents Washington, D.C. 20231

Dear Sir:

This prior art statement is filed under 37 C.F.R. §§1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56.

In the judgment of the undersigned, the references listed on the attached Form PTO-1449 may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this statement or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102.



- 1. U.S. Patent 6,169,088, granted January 2, 2001.
- 2. U.S. Patent No. 5,354,747, granted August 11, 1994.
- 3. EP 0 790 240 A1, published August 20, 1997.
- 4. EP 0 100 200 A1, published February 8, 1984.
- 5. EP 0 100 200 B1, published May 5, 1987.
- 6. WO 96/02525 A1, published February 1, 1996.
- 7. WO 99/51582, published October 14, 1999.
- 8. WO 00/17163, published March 30, 2000.
- 9. WO 00/27822, published May 18, 2000.
- 10. WO 00/63171, published October 26, 2000.
- 11. WO 94/29286, published December 22, 1994.
- 12. WO 96/01820, published January 25, 1996.
- 13. WO 98/14431, published April 9, 1998.
- 14. WO 99/64394, published December 16, 1999.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the



guidelines for citation have been fully complied with. This is requested so that each

Respectfully submitted, McDONNELL BOEHNEN **HULBERT & BERGHOFF** 300 South Wacker Drive Chicago, Illinois 60606 (312) 913-0001

Dated: April 10, 2002

By:

Steven J. Sarussi Reg. No. 32,784

GP/1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 02-090-B)

In re Application of:

Bakthavatchalam et al.

Serial No.: 09/910,442

Filed: July 20, 2001

For: Capsaicin Receptor Ligands

Group Art Unit: 1614

Examiner: not assigned

Commissioner for Patents Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

- 1. We are transmitting herewith the attached:
 - a. Information Disclosure Statement;
 - b. Copy Fourteen (14) cited references; and
 - c. Postcard.
- 2. With respect to additional fees:
 - XA. No fees are necessary at this time.
 - B. Charge the total additional fee to our Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
- 3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
- 4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 or this)10th day of April 2002.

Bv

Steven J. Sáruss

Reg. No/32,784